NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Provisional Single Technology Appraisal (STA)

Azacitidine for high risk patients with myelodysplastic syndrome and acute myeloid leukaemia

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Pfizer (azacitidine)	Age Concern Cymru
, ,	Board of Community Health Councils in
Patient/carer groups	Wales
Action for Sick Children	British National Formulary
Afiya Trust	Department of Health, Social Services
 African Caribbean Leukaemia Trust 	and Public Safety for Northern Ireland
(ACLT)	 Medicines and Healthcare products
Age Concern England	Regulatory Agency
Anthony Nolan Trust	 National Association of Primary Care
Association for Children with Life	National Public Health Service for
Threatening or Terminal Conditions	Wales
(ACT)	NHS Alliance
Black Health Agency	NHS Confederation
British Ethnic Health Awareness	NHS Purchasing and Supply Agency
Foundation (BEHAF)	NHS Quality Improvement Scotland
Cancer Black Care	Scottish Medicines Consortium
Cancer Equality	
Cancer Voices	Comparator manufacturers
CancerACTIVE	Cephalon (doxorubicin)
Cancerbackup	Hospira UK (cytarabine, doxorubicin)
Children with Leukaemia	Pharmacia (cytarabine, doxorubicin)
Chinese National Healthy Living	Schering Plough (doxorubicin)
Centre	Winthrop Pharmaceuticals UK
CLIC Sargent Contains of ladian Constitutions	(daunorubicin)
Confederation of Indian Organisations	Wockhardt UK (doxorubicin)
Counsel and Care The all the second se	Zeneus (doxorubicin)
Equalities National Council City The Olithan Large Park	Polovant recognish groups
Gift – The Children's Transplant Gharity	Relevant research groups Elimination of Leukaemia Fund
Charity	
Helen Rollason Heal Cancer Charity	Institute of Cancer ResearchLeukaemia Busters
Help the Aged Aged Aged	
Leukaemia CARE Leukaemia CARE	Leukaemia Research Fund MRC Clinical Triple Unit
Leukaemia Society (UK) Magazillar Consort	MRC Clinical Trials Unit
Macmillan Cancer Support	National Cancer Research Institute

National Institute for Health and Clinical Excellence

Consultation on the draft scope and provisional matrix for the appraisal of azacitidine for the treatment of myelodysplastic syndrome and acute myeloid leukaemia

Issue date: April 2008 Page 1 of 4

Consultees Commentators (no right to submit or appeal) Maggie's Centres Policy Research Institute on Ageing and Marie Curie Cancer Care **Ethnicity** Muslim Council of Great Britain Research Institute of the Care of the Elderly Muslim Health Network **National Cancer Alliance Evidence Review Group** National Children's Bureau Evidence Review Group tbc National Council for Palliative Care National Coordinating Centre for Health NCH – The Children's Charity **Technology Assessment** South Asian Health Foundation Specialised Healthcare Alliance **Associated Guideline Groups** Sue Ryder Care National Collaborating Centre for **Tenovus Cancer Information Centre** Cancer Transplant Support Network **UK Transplant** Associated Public Health Groups WellChild tbc Professional groups Association of Cancer Physicians British Association for Services to the Elderly **British Geriatrics Society** British Oncological Association (BOA) British Psychosocial Oncology Society British Society for Haematology Cancer Networks Pharmacists Forum Cancer Research UK Children's Cancer and Leukaemia Group Royal College of General Practitioners Royal College of Nursing Royal College of Paediatric and Child Health Royal College of Pathologists Royal College of Physicians, Medical **Oncology Joint Special Committee** Royal Pharmaceutical Society Royal Society of Medicine -Intellectual Disabilities Forum United Kingdom Oncology Nursing Society **United Kingdom Clinical Pharmacy** Association

Issue date: April 2008 Page 2 of 4

Consultees	Commentators (no right to submit or appeal)
Others	
Department of Health	
Harrow PCT	
North Tees PCT	
Welsh Assembly Government	

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence

Issue date: April 2008 Page 4 of 4

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.